Type 2 Diabetes, Atrial Fibrillation, and Direct Oral Anticoagulation.
Dana PrídavkováMatej SamošTomáš BolekIngrid ŠkorňováJana ŽolkováPeter KubiszJán StaškoMarián MokáňPublished in: Journal of diabetes research (2019)
Type 2 diabetes (T2D) is an independent risk factor of stroke and systemic embolism in patients with atrial fibrillation (AF), and T2D patients with AF-associated stroke seem to have worse clinical outcome and higher risk of unfavorable clinical course compared to individuals without this metabolic disorder. Long-term anticoagulation is indicated in majority of T2D patients with AF to prevent adverse AF-associated embolic events. Direct oral anticoagulants (DOACs), direct oral thrombin inhibitor dabigatran, and direct oral factor Xa inhibitors, rivaroxaban, apixaban, and edoxaban, have emerged as a preferred choice for long-term prevention of stroke in AF patients offering potent and predictable anticoagulation and a favorable pharmacology with low risk of interactions. This article reviews the current data regarding the use of DOACs in individuals with T2D and AF.
Keyphrases
- atrial fibrillation
- direct oral anticoagulants
- type diabetes
- oral anticoagulants
- left atrial
- catheter ablation
- left atrial appendage
- venous thromboembolism
- heart failure
- end stage renal disease
- percutaneous coronary intervention
- ejection fraction
- newly diagnosed
- cardiovascular disease
- risk factors
- chronic kidney disease
- glycemic control
- peritoneal dialysis
- prognostic factors
- electronic health record
- emergency department
- coronary artery disease
- artificial intelligence
- machine learning
- left ventricular
- blood brain barrier
- skeletal muscle
- big data
- adipose tissue
- pulmonary embolism
- anti inflammatory
- metabolic syndrome